Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 9, 2004, Pages 1033-1039

  Firpi, R J ^a   Tran, T T ^a   Flores, P ^a   Nissen, N ^a   Colquhoun, S ^a   Shackleton, C ^a   Martin, P ^a   Vierling, J M ^a   Poordad, F F ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CYCLOSPORIN A; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANAMNESIS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; ENDOCARDITIS; FEMALE; GRAFT REJECTION; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS;

EID: 2442695089     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01923.x     Document Type: Article

References (18)

1. Vazquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm 2000; 57: 437-48.
2. Neuhaus P, Klupp J & Langrehr JM. mTORinhibitors: an overview. Liver Transpl 2001; 7: 473-84.
3. Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation - use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6: 734-40.
4. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973.
5. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 48-50.
6. Murgia MG, Jordan S & Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209-16.
7. MadDonald ASfor the Rapamune Global Study Group. A world-wide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-80.
8. Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 401-8.
9. Watson CJE, Friend PJ, Jamienson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505-9.
10. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701-8.
11. Trotter JF, Washs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-51.
12. Brattström C, Wilczek H, Tyden G, Böttiger Y, Säwe J, Groth CG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998; 30: 3950-1.
13. Meier-Kriesche HU. Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole blood concentrations. Clinical Therapeutics 2000; 22(Suppl. B): B93-100.
14. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination for renal transplantation. Transplantation 1998; 66: 1040-6.
15. Tur MD, Garrigue V, Vela C. et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 2000; 32: 2783-4.
16. Hoogeveen RC. Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Clin Transpl 2001; 72: 1244-50.
17. Wilson JD. Plasma protein: apolipoproteins, receptors, and enzymes. In: Williams RH, ed. Textbook of Endocrinology. 9th edn. W.B. Saunders Company, 1998: 1103.
18. Witzum JL, Steinberg D. The hyperlipoproteinemias. In: Cecil R, ed. Textbook of Medicine 2000, 21st edn. W.B. Saunders Company, 1090-100.